MRS, VENOM and MURA Tokens to be Unlocked in Large Quantities This Week
According to BWEnews, data from Token Unlocks shows that this week, MRS, VENOM, and MURA, among others, will undergo a large-scale token unlock worth over 100 million US dollars in total, including:
Metars Genesis (MRS) will unlock 10 million tokens on April 22 at 8:00 (UTC+8), valued at approximately 122 million US dollars, accounting for 0% of the circulation (specific situation unknown);
Venom (VENOM) will unlock 59.26 million tokens on April 25 at 16:00 (UTC+8), valued at about 8.18 million US dollars, accounting for 2.86% of the circulation;
Murasaki (MURA) will unlock 10 million tokens on April 23 at 8:00 (UTC+8), valued at approximately 4.01 million US dollars, accounting for 1% of the circulation;
IOTA (IOTA) will unlock 15.16 million tokens on April 30 at 8:00 (UTC+8), valued at about 2.54 million US dollars, accounting for 0.41% of the circulation.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Intel Confirms Advancement of Musk's "Terafab" Chip Plan Amid Stock Price Pressure
Intel CEO Pat Gelsinger stated that the company will continue to participate in Elon Musk's Terafab project. Previously, Musk revealed ongoing discussions with TSMC about potential collaboration, which raised market concerns over Intel's position in the project. As a result, Intel's stock price once dropped by 3.9%.
Gold Price Forecast: XAU/USD retraces gains and nears two-month lows at $4,104
BUZZ-Caribou shares plunge as company explores sale and cancels cancer project
October 7 - ** Caribou Biosciences (CRBU.O) shares fell 35.9% in pre-market trading to $0.72 ** Caribou Biosciences announced late Tuesday that it is exploring strategic options, including a potential sale, merger, or other transactions, to maximize shareholder value ** Caribou said it plans to halt development of its allogeneic CAR-T cell therapy programs, including vispa-cel for non-Hodgkin lymphoma and CB-011 for multiple myeloma ** Caribou also stated it will lay off employees and cut costs, with most layoffs expected to be completed by Q4 2026 ** As of June 30, the company held $113.8 millions in cash, cash equivalents, and marketable securities ** As of the previous trading day's close, the company's share price had dropped about 28% year-to-date (Note: For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automated translations may be inaccurate or lack necessary context, Reuters does not guarantee the accuracy of automated translation texts and provides them only for reader convenience. Reuters assumes no responsibility for any damages or losses resulting from the use of automated translation features.)
Crypto prices
More
